



RNDr. Rostislav Skrabana, PhD graduated in Physical Chemistry at Charles University, Prague, Czech Republic and obtained his PhD in Molecular Biology from Faculty of Natural Sciences, Comenius University in Bratislava, Slovakia in 2005. Since 2013, Dr. Skrabana has been a group leader of the Structural Biology of Neurodegeneration group at the Institute of Neuroimmunology of Slovak Academy of Sciences (INSAS) in Bratislava. During his PhD project, he promoted the study of intrinsic disorder of tau protein, the major player in tauopathies. For more than ten years he was employed in biotechnological company Axon Neuroscience (Vienna, Bratislava) where he participated on the preclinical and

clinical development of the active and passive vaccines targeting neurodegeneration and viral threats. Currently, the projects investigated by his groups at INSAS employ methods of protein biophysical chemistry, protein biotechnology, biophysics and structural biology to characterize disordered proteins of medical importance and the protein flexibility in general. Dr. Skrabana's team is collaborating with NMR groups studying intrinsically disordered proteins in Brno (Prof. Zidek, Dr. Kaderavek, Dr. Hritz) and in Riga (Dr. Jaudzems, Dr. Lends), with the molecular dynamics group in Mendoza (Dr. Barrera, Dr. Bustos), with X-ray crystallography group in Vestec near Prague (Dr. Dohnalek) and with several biophysical research groups in Slovakia. Dr. Skrabana is an active member of the Czech Society for Structural Biology and Slovak Biophysical Society. He is a co-author of three patents in the field of immunotherapy of tauopathies and COVID-19 and of more than 50 scientific publications; his H-index is 21 (Clarivate). Dr. Skrabana supervised over 15 master and graduated student projects involving intrinsically disordered proteins and immunotherapy. He has been principal investigator or co-investigator of several national and international grants (VEGA, APVV, ICGEB, COST, Horizon2020).